Cytek Biosciences, Inc. (CTKB)
CTKB Stock Price Chart
Explore Cytek Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CTKB price movements and trends.
CTKB Company Profile
Discover essential business fundamentals and corporate details for Cytek Biosciences, Inc. (CTKB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
23 Jul 2021
Employees
663.00
Website
https://cytekbio.comCEO
Wenbin Jiang
Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
CTKB Financial Timeline
Browse a chronological timeline of Cytek Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Nov 2025
EPS estimate is $0.01, while revenue estimate is $51.49M.
Earnings released on 6 Aug 2025
EPS came in at $0.01 surpassing the estimated -$0.02 by +150.00%, while revenue for the quarter reached $45.60M , missing expectations by -1.61%.
Earnings released on 8 May 2025
EPS came in at -$0.09 falling short of the estimated -$0.04 by -125.00%, while revenue for the quarter reached $41.46M , missing expectations by -2.83%.
Earnings released on 27 Feb 2025
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $57.48M , missing expectations by -3.21%.
Earnings released on 5 Nov 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +166.67%, while revenue for the quarter reached $51.50M , missing expectations by -15.42%.
Earnings released on 6 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.03 by -166.67%, while revenue for the quarter reached $46.62M , missing expectations by -8.05%.
Earnings released on 8 May 2024
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $44.86M , beating expectations by +2.91%.
Earnings released on 13 Mar 2024
EPS came in at $0.07 surpassing the estimated $0.03 by +133.33%, while revenue for the quarter reached $58.23M , beating expectations by +2.92%.
Earnings released on 7 Nov 2023
EPS came in at $0.01 surpassing the estimated -$0.33 by +103.00%, while revenue for the quarter reached $48.00M , missing expectations by -13.48%.
Earnings released on 8 Aug 2023
EPS came in at $0.01 surpassing the estimated -$0.01 by +200.00%, while revenue for the quarter reached $49.69M , missing expectations by -13.79%.
Earnings released on 9 May 2023
EPS came in at -$0.03 falling short of the estimated -$0.02 by -100.00%, while revenue for the quarter reached $37.09M , missing expectations by -18.88%.
Earnings released on 28 Feb 2023
EPS came in at $0.07 surpassing the estimated $0.05 by +40.00%, while revenue for the quarter reached $164.04M , beating expectations by +247.90%.
Earnings released on 9 Nov 2022
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $40.48M , missing expectations by -6.49%.
Earnings released on 10 Aug 2022
EPS came in at $0.03 surpassing the estimated $0.02 by +79.96%, while revenue for the quarter reached $40.16M , beating expectations by +1.34%.
Earnings released on 11 May 2022
EPS came in at $0.01 surpassing the estimated $0.00 by +300.00%, while revenue for the quarter reached $35.06M , beating expectations by +7.86%.
Earnings released on 23 Feb 2022
EPS came in at $0.05 surpassing the estimated $0.04 by +19.99%, while revenue for the quarter reached $38.89M , beating expectations by +6.79%.
Earnings released on 8 Nov 2021
EPS came in at $0.02 falling short of the estimated $0.02 by -14.27%, while revenue for the quarter reached $34.38M , beating expectations by +13.05%.
Earnings released on 3 Sept 2021
EPS came in at $0.02 , while revenue for the quarter reached $30.41M .
Earnings released on 27 Jul 2021
EPS came in at $0.00 , while revenue for the quarter reached $24.27M .
Earnings released on 31 Dec 2020
EPS came in at $0.05 , while revenue for the quarter reached $30.62M .
Earnings released on 30 Sept 2020
EPS came in at $0.18 , while revenue for the quarter reached $25.10M .
CTKB Stock Performance
Access detailed CTKB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.